Anixa Biosciences begins dosing in second cohort of ovarian cancer CAR-T trial

Anixa Biosciences has commenced treatment for the fourth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. The first-in-human trial is enrolling patients with recurrent/resistant ovarian cancer who have progressed on at least two prior therapies. The CAR T was safe and tolerable in the first three patients treated. The fourth patient, the first patient enrolled in the second cohort, received triple the dose of CAR-T cells compared with the dose of the first cohort. Anixa’s Follicle Stimulating Hormone Receptor -mediated CAR-T technology, also known as chimeric endocrine receptor T-cell, differs from traditional CAR-T therapy by targeting FSHR, which research indicates is expressed on ovarian cells, as well as in the vasculature of tumors.